Variable modulation of opioid brain uptake by P-glycoprotein in mice

Biochemical Pharmacology

Volumn 67, Issue 2, 2004, Pages 269-276

  Dagenais, Claude ^a   Graff, Candace L ^b   Pollack, Gary M ^b  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Analgesia; Blood brain barrier; Efflux; Opioids; P glycoprotein; Permeability

Indexed keywords

BREMAZOCINE; DELTA OPIATE RECEPTOR; DELTORPHIN; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; FENTANYL; GLYCOPROTEIN P; KAPPA OPIATE RECEPTOR; LOPERAMIDE; METHADONE; MORPHINE; MU OPIATE RECEPTOR; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALTRINDOLE; OPIATE; PETHIDINE; QUINIDINE; RECEPTOR SUBTYPE; SNC 121; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN PERFUSION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STRAIN DIFFERENCE; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; WILD TYPE;

EID: 1642579542     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.08.027     Document Type: Article

References (42)

1. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39:1999;361-398.
2. Schinkel A.H. The physiological function of drug-transporting P-glycoproteins. Semin. Cancer Biol. 8:1997;161-170.
3. Schinkel A.H. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev. 36:1999;179-194.
4. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U.S.A. 86:1989;695-698.
5. Rao V.V., Dahlheimer J.L., Bardgett M.E., Snyder A.Z., Finch R.A., Sartorelli A.C., Piwnica-Worms D. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc. Natl. Acad. Sci. U.S.A. 96:1999;3900-3905.
6. Koszdin K.L., Shen D.D., Bernards C.M. Spinal cord bioavailability of methylprednisolone after intravenous and intrathecal administration: the role of P-glycoprotein. Anesthesiology. 92:2000;156-163.
7. Huang J.T., Takemori A.E. Accumulation of methadone by the choroid plexus in vitro. Neuropharmacology. 14:1975;241-246.
8. Lin J.H. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv. Drug Deliv. Rev. 55:2003;53-81.
9. Callaghan R., Riordan J.R. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J. Biol. Chem. 268:1993;16059- 16064.
10. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A., Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:1995;1698-1705.
11. Xie R., Hammarlund-Udenaes M., de Boer A.G., de Lange E.C. The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br. J. Pharmacol. 128:1999;563-568.
12. Letrent S.P., Pollack G.M., Brouwer K.R., Brouwer K.L. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm. Res. 15:1998;599-605.
13. Letrent S.P., Pollack G.M., Brouwer K.R., Brouwer K.L. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab. Dispos. 27:1999;827-834.
14. Letrent S.P., Polli J.W., Humphreys J.E., Pollack G.M., Brouwer K.R., Brouwer K.L. P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells. Biochem. Pharmacol. 58:1999;951-957.
15. Zong J., Pollack G.M. Morphine antinociception is enhanced in mdr1a gene-deficient mice. Pharm. Res. 17:2000;749-753.
16. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:1996;2517-2524.
17. Chen C., Pollack G.M. Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice. J. Pharmacol. Exp. Ther. 287:1998;545-552.
18. Chen C., Pollack G.M. Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation. Pharm. Res. 16:1999;296-301.
19. Jonker J.W., Wagenaar E., van Deemter L., Gottschlich R., Bender H.M., Dasenbrock J., Schinkel A.H. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgesic drug. Br. J. Pharmacol. 127:1999;43-50.
20. Thompson S.J., Koszdin K., Bernards C.M. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology. 92:2000;1392-1399.
21. Henthorn T.K., Liu Y., Mahapatro M., Ng K.Y. Active transport of fentanyl by the blood-brain barrier. J. Pharmacol. Exp. Ther. 289:1999;1084-1089.
22. Lang V.B., Langguth P., Ottiger C., Wunderli-Allenspach H., Rognan D., Rothen-Rutishauser B., Perriard J.C., Lang S., Biber J., Merkle H.P. Structure-permeation relations of met-enkephalin peptide analogues on absorption and secretion mechanisms in Caco-2 monolayers. J. Pharm. Sci. 86:1997;846-853.
23. Bouer R., Barthe L., Philibert C., Tournaire C., Woodley J., Houin G. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam. Clin. Pharmacol. 13:1999;494-500.
24. Wandel C., Kim R., Wood M., Wood A. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology. 96:2002;913-920.
25. Way W, Fields H, Schumacher M. Opioid alagesics and antagonists. In: Katzung B, editor. Basic and clinical pharmacology. New York: Lange Medical Books/McGraw Hill; 2001. p. 512-31.
26. Dagenais C., Rousselle C., Pollack G.M., Scherrmann J.M. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J. Cereb. Blood Flow Metab. 20:2000;381-386.
27. Dagenais C., Zong J., Ducharme J., Pollack G.M. Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds. Pharm. Res. 18:2001;957-963.
28. Wang C, Willis D, Loverland W. Nuclear statistics, radiotracer methodology in the biological, environmental and physical sciences. Englewood Cliffs: Prentice-Hall; 1975.
29. Oldendorf W.H., Hyman S., Braun L., Oldendorf S.Z. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science. 178:1972;984-986.
30. Roy S.D., Flynn G.L. Solubility and related physicochemical properties of narcotic analgesics. Pharm Res. 5:1988;580-586.
31. Kristensen K., Christensen C.B., Christrup L.L. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci. 56:1995;PL45-PL50.
32. Ecker G., Chiba P. Structure-activity-relationship studies on modulators of the multidrug transporter P-glycoprotein - an overview. Wiener Klinische Wochenschrift. 107:1995;681-686.
33. Matheny C.J., Lamb M.W., Brouwer K.R., Pollack G.M. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy. 21:2001;778-796.
34. Maurer P.M., Bartkowski R.R. Drug interactions of clinical significance with opioid analgesics. Drug Safety. 8:1993;30-48.
35. Huwyler J., Drewe J., Klusemann C., Fricker G. Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium. Br. J. Pharmacol. 118:1996;1879-1885.
36. Lotsch J., Tegeder I., Angst M.S., Geisslinger G. Antinociceptive effects of morphine-6-glucuronide in homozygous MDR1a P-glycoprotein knockout and in wildtype mice in the hotplate test. Life Sci. 66:2000;2393-2403.
37. Fromm M.F., Eckhardt K., Li S., Schanzle G., Hofmann U., Mikus G., Eichelbaum M. Loss of analgesic effect of morphine due to coadministration of rifampin. Pain. 72:1997;261-267.
38. Inturrisi C.E., Colburn W.A., Kaiko R.F., Houde R.W., Foley K.M. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin. Pharmacol. Ther. 41:1987;392-401.
39. Cirella V.N., Pantuck C.B., Lee Y.J., Pantuck E.J. Effects of cyclosporine on anesthetic action. Anesth. Analg. 66:1987;703-706.
40. Mayer U., Wagenaar E., Dorobek B., Beijnen J.H., Borst P., Schinkel A.H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest. 100:1997;2430-2436.
41. Sadeque A.J., Wandel C., He H., Shah S., Wood A.J. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther. 68:2000;231-237.
42. Yamazaki M., Neway W.E., Ohe T., Chen I., Rowe J.F., Hochman J.H., Chiba M., Lin J.H. In vitro substrate identification studies for p-glycoprotein- mediated transport: species difference and predictability of in vivo results. J. Pharmacol. Exp. Ther. 296:2001;723-735.